June 28 (Bloomberg) — Justin Smith, an analyst at MF Global UK Ltd., discusses the outlook for the U.S. Food and Drug Administration’s Oncologic Drugs advisory panel hearing on Roche Holding AG's breast-cancer drug Avastin.   The panel heard from more than 30 speakers today to open a two-day appeals hearing at the agency\u2019s headquarters in Silver Spring, Maryland. Basel, Switzerland-based Roche is contesting the FDA\u2019s Dec. 16 decision to withdraw Avastin\u2019s conditional approval in breast cancer after…